TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.

Martin J Edelman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.